--- title: "Novo Nordisk's weight-loss drug Wegovy approved by UK drug pricing regulator for heart disease, expanding eligible population by 1.2 million" type: "News" locale: "en" url: "https://longbridge.com/en/news/281381740.md" description: "Novo Nordisk's weight-loss drug Wegovy has been approved by UK drug pricing regulator NICE to prevent heart attacks and strokes. This new recommendation will make the drug accessible to approximately 1.2 million people through the NHS, significantly expanding its reach. Novo Nordisk's shares in Copenhagen rose as much as 4% on Wednesday" datetime: "2026-04-01T13:52:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281381740.md) - [en](https://longbridge.com/en/news/281381740.md) - [zh-HK](https://longbridge.com/zh-HK/news/281381740.md) --- # Novo Nordisk's weight-loss drug Wegovy approved by UK drug pricing regulator for heart disease, expanding eligible population by 1.2 million England's drug pricing regulator has recommended Novo Nordisk's weight-loss drug Wegovy for the prevention of heart attacks and strokes. The new recommendation from the National Institute for Health and Care Excellence (NICE) will significantly expand Wegovy's coverage within the country's National Health Service (NHS), with NICE deeming that approximately 1.2 million people could be eligible to use the drug to help prevent further heart attacks or strokes as it is used for this condition. Novo Nordisk's stock, listed in Copenhagen, rose as much as 4% on Wednesday. ### Related Stocks - [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md) - [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) ## Related News & Research - [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md) - [](https://longbridge.com/en/news/286601439.md)